Alcohol dependence is associated with deficits in glutamate uptake and impairment of glutamate homeostasis in different brain reward regions. Glutamate transporter subtype 1 (GLT-1), cystine-glutamate exchanger (xCT) and glutamate/aspartate transporter (GLAST) are one of the key players in regulating extracellular glutamate concentration in the brain. Parenteral treatment with ceftriaxone, ␤-lactam antibiotic, has been reported to attenuate ethanol consumption and reinstatement to cocaine-seeking behavior, in part, by restoring the expression of GLT-1 and xCT in mesocorticolimbic brain regions in rats. In this study, we focused to test Augmentin (amoxicillin/clavulanate), which can be administered orally to subjects. Therefore, we examined the effects of orally administered Augmentin on ethanol intake as well as GLT-1, xCT and GLAST expression in male alcohol-preferring (P) rats. We found that orally administered Augmentin significantly attenuated ethanol consumption in P rats as compared to the vehicle-treated group. Importantly, the attenuation in ethanol consumption was associated with a significant upregulation of GLT-1 and xCT expression in nucleus accumbens (NAc) and prefrontal cortex (PFC). There was no effect of orally administered Augmentin on GLAST expression in either NAc or PFC. These findings present strong evidence that oral administration of Augmentin can be used as an alternative to parenteral treatment.
Introduction
Ethanol and other drugs of abuse can induce a dysregulation of glutamatergic neurotransmission in mesocorticolimbic brain regions, including nucleus accumbens (NAc) and prefrontal cortex (PFC) [1, 2] . Several studies have shown that ethanol exposure is associated with elevated extracellular glutamate concentration in central brain reward regions, such as NAc, hippocampus and ventral tegmental area [3] [4] [5] [6] [7] . Studies from our laboratory have revealed that chronic ethanol consumption reduced the expression of the major glutamate transporters, such as glutamate transporter 1 (GLT-1, its human homolog is excitatory amino acid transporter 2, EAAT2) [8, 9] . GLT-1 is responsible for the uptake of the majority of extracellular glutamate concentration [10] [11] [12] . Thus, compounds that upregulate GLT-1 expression in mesocorticolim-bic brain regions may serve as a potential treatment of ethanol dependence.
Cystine-glutamate exchanger (xCT) plays a major part in maintaining basal glutamate concentration [13, 14] . It is important to note that xCT exchanges internal glutamate for the external cystine to maintain glutamate homeostasis [10, 15] . Previous study from our laboratory demonstrated that chronic ethanol exposure downregulated xCT expression in both NAc and PFC [16] . In addition, xCT was downregulated in the NAc following withdrawal of cocaine [17] . Glutamate/aspartate transporter (GLAST, its human homologs is EAAT1), is another glutamate transporter that is known to control synaptic glutamate concentration and is expressed mainly in the cerebellum [18] .
Alcohol-preferring (P) rats line is a selectively bred line of rats, which meets all criteria for a suitable animal model for alcoholism. P rats exhibit high alcohol-seeking behavior and consume levels of ethanol during adolescence equivalent to that observed in adulthood. The P rats line also displays excessive binge-like ethanol drinking with average ethanol intake of more than 5 g/kg/day, attaining blood ethanol concentration of 200 mg% [19, 20] . Fig. 1 . Timeline of oral gavage of Augmentin experiment. Rats were exposed to free access of (15% and 30% v/v) ethanol, water and food for five weeks. Week 4 and 5 ethanol drinking and water measurements were used as baseline. On Week 6, rats were randomly assigned to receive either Augmentin (100 mg/kg) or vehicle through the oral gavage route for five consecutive days. Vehicle and Augmentin treated rats were then euthanized (24 h following the last vehicle/Augmentin oral gavage) by CO2 inhalation and rapidly decapitated.
␤-lactam antibiotics have been reported to reduce ethanol consumption, at least in part, through upregulation of GLT-1 and xCT expression [16, [21] [22] [23] [24] [25] . It is noteworthy that ceftriaxone parenteral treatment attenuated ethanol consumption and cocaine-seeking behavior, in part, by restoring glutamate homeostasis in mesocorticolimbic regions in rats [16, 26] . However, the unavailability of oral dosage form is considered as a major limitation for ceftriaxone treatment. To the best of our knowledge, no previous studies have investigated the effect of orally administered ␤-lactam antibiotic on either ethanol consumption or other drugs of abuse. Moreover, the effects of orally administered ␤-lactam antibiotic on the expression of glutamate transporters have not been studied yet. Therefore, in this study, we examined the effects of orally administered Augmentin (amoxicillin/clavulanate) on ethanol intake, GLT-1, xCT and GLAST expression in P rats.
Materials and methods

Animals
Male P rats were obtained from Indiana University, School of Medicine (Indianapolis, IN, USA) at the age of 21-30 days, and housed in the Department of Laboratory Animal Resources, University of Toledo, Health Science Campus. All animals were housed in a plastic corn-cob bedding tubs and had an access to food and water ad lib throughout the experiment. The room temperature was maintained at 21 • C and 50% humidity with a 12-h light-dark cycle. At the age of 90 days, male P rats were individually housed and randomly divided into two groups; (a) control group, which received oral gavage of water 1 ml/kg/day for 5 days (n = 7) (control or vehicle); (b) Treatment group, which received Augmentin (100 mg/kg/day) through oral gavage for 5 days (n = 7) (Aug). It is important to note that i.p. injections of Augmentin at dose of 100 mg/kg for 5 days reduced ethanol intake and upregulated GLT-1 and xCT expression in the NAc and the PFC [25] . All rats had a voluntary uninterrupted access to ethanol, water and food throughout the experiment. All animal procedures were in compliance and approved by the Institutional Animal Care and Use committee of The University of Toledo in accordance with the guidelines of the Institutional Animal Care and Use Committee of the National Institutes of Health and the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, Commission on Life Sciences, 1996).
Behavioral drinking paradigms
At the age of 90 days, rats were exposed to a free choice of ethanol (15% and 30% v/v), water and food for a period of five weeks. After the third week of drinking paradigm, ethanol and water intakes were measured three times a week for two weeks to obtain baseline intake. Ethanol and water intake measurements were expressed as g/kg/day. Animals with a baseline ethanol intake of less than 4 g/kg/day were not included in the study as adopted in previous studies [8, 9, 27] . During Week 6, vehicle or Augmentin was administered through oral gavage for 5 consecutive days. In addition, during Week 6, ethanol and water intakes as well as animal body weight were measured every day through the last day of the experiment as illustrated in Fig. 1 .
Brain tissue harvesting
Rats were euthanized using carbon dioxide inhalation 24 h after the last administered dose of vehicle or Augmentin and rapidly decapitated. Brains were then immediately frozen at −80 • C. The NAc and PFC were further micropunched using a cryostat machine according to the Rat Brain Atlas [28] . Extracted brain regions were stored at −80 • C for western blot analysis.
Western blot protocol for detection of GLT-1, xCT and GLAST
Isolated NAc and PFC tissues were examined for the changes in GLT-1, xCT and GLAST expression relative to total ␤-tubulin using Western blotting procedure. Briefly, extracted brain regions were lysed using regular lysis buffer as described in [27] . Isolated protein samples were then mixed with 5X laemmli loading dye and loaded in polyacrylamide gels for electrophoresis separation. Proteins were then transferred on PVDF membranes electrophoretically (Bio-Rad, Hercules, CA). Membranes were then blocked with 3% fat-free milk in TBST (50 mM Tris HCl; 150 mM NaCl, pH 7.4; 0.1% Tween 20) for 30 min at room temperature. Consequently, membranes were incubated overnight at 4 • C with one of the following primary antibodies: guinea pig anti-GLT1 (1:5000), rabbit antixCT antibody (1:1000), and rabbit anti-EAAT1 (GLAST) antibody (1:5000). Membranes were then washed with TBST and blocked with 3% milk in TBST for 30 min. Membranes were further incubated with secondary antibodies for 90 min at room temperature. The corresponding secondary antibodies are: guinea pig anti-GLT-1 secondary antibody (1:5000) and rabbit anti-xCT secondary antibody (1:5000). ␤-tubulin was used as loading control (1:5000). Membranes were then exposed to the chemiluminescent substrate and further developed on the SRX-101A machine. The detected bands were quantified using MCID system and the results were expressed as a percentage of the ratio of tested protein/␤-tubulin, relative to control group (100% control-value).
Statistical analyses
Statistical analysis using two-way repeated measure ANOVA was conducted to determine the main effect of day x treatment interaction on water intake, ethanol intake, ethanol preference, and body weight comparisons between control and Augmentin groups. Bonferroni multiple comparisons post-hoc test was used whenever a significant main effect or interaction was found. An unpaired t-test was used to analyze Western blot data (GLT-1/␤-tubulin, xCT/␤-tubulin, and GLAST/␤-tubulin) between control and Augmentin groups. All statistical analyses were based on p < 0.05 level of significance. Data are represented as mean ± SEM.
Results
Effect of oral gavage of Augmentin on average ethanol intake
The average ethanol consumption over the last two weeks of drinking paradigm was considered as the baseline. P rats were then divided into two groups: control and oral gavage of Augmentin treatment groups. Statistical analysis using two-way repeated measure ANOVA revealed a significant main effect of Days [F (1, 5) = 3.786, p < 0.01] and significant Treatment x Day interaction [F (1, 5) = 3.950, p < 0.001]. Bonferroni multiple comparisons post-hoc test revealed a significant reduction in ethanol consumption in the treatment group as compared to the control group started on Day 2 (48 h after the first oral gavage of Augmentin) through the last day of the experiment, (p < 0.001), (Fig. 2A ).
Effect of oral gavage of Augmentin on ethanol preference
The percentage of ethanol preference was calculated daily by the following equation: [total ethanol consumption/total fluid consumption x 100] using the daily ethanol and water consumption for each rat as described previously [29] . Two-way repeated measure ANOVA revealed a significant main effect of Day [F (1, 5) = 7.467, p < 0.0001] and significant Treatment x Day interaction [F (1, 5) = 8.111, p < 0.0001]. Bonferroni multiple comparisons posthoc test revealed a significant reduction in ethanol preference from Day 2 through the last day of the experiment in Augmentin group (p < 0.01) as compared to the control group (Fig. 2B ). (Fig. 2C) . (Fig. 2D) . Fig. 2 . Changes in the average daily ethanol intake, ethanol preference water consumption and average body weight following oral gavage of Augmentin in P rats exposed to free choice of ethanol and water for 5 weeks. A) Effect of Augmentin treatment on average daily ethanol intake as compared to control (g/kg/day) in P rats. Two-way repeated measure ANOVA followed by Bonferroni multiple comparisons post-hoc test revealed a significant reduction in ethanol consumption in Augmentin group as compared to control group starting Day 2 through Day 5 (p < 0.001). B) Effect of oral gavage of Augmentin on percent of ethanol preference in male P rats. Two-way repeated measure ANOVA followed by Bonferroni multiple comparisons post-hoc test revealed a significant decrease in ethanol preference in oral gavage of Augmentin group from Day 2 through Day 5 as compared to the control group. C) Effect of Augmentin treatment on water consumption as compared to control group (g/kg/day). Two-way repeated measure ANOVA followed by Bonferroni multiple comparisons post-hoc test revealed a significant increase in water intake in all rats treated with Augmentin (p < 0.001) as compared to the control group from Day 2 throughout Day 5. D) Effect of oral gavage of Augmentin on average body weight of P rats. Two-way repeated measure ANOVA followed by Bonferroni multiple comparisons post-hoc test showed no significant difference in average body weight between the Augmentin treatment and control groups. Data are represented as mean ± SEM (**p < 0.01, ***p < 0.001, ****p < 0.0001), (n = 7 for each group).
Effect of oral gavage of Augmentin on water intake
Two-way repeated measure ANOVA demonstrated a significant effect of Days [F (1, 5) = 6.325, p < 0.0001] and significant Treatment x Day interaction [F (1, 5)= 11.25, p < 0.0001]. Bonferroni posthoc test revealed a significant increase in water intake in all rats treated with Augmentin as compared to rats treated with vehicle (p < 0.001). This increase in water intake in Augmentin group was detected during Week 6 as compared to the control group. However, statistical analysis revealed a significant increase in water intake from Day 2 throughout Day 5 as compared to the control group
Effects of oral gavage of Augmentin on GLT-1, xCT and GLAST expression in NAc and PFC
Statistical analysis using independent t-test revealed a significant upregulation of GLT-1 expression in the NAc in Augmentin-treated group as compared to the control group (Fig. 3A,B) , (t(12) = 3.017, p < 0.05). In addition, statistical analysis using independent t-test revealed a significant upregulation of GLT-1 expression in the PFC in Augmentin-treated group as compared to control group (Fig. 4A,B) , (t(12) = 3.893, p < 0.01).
Independent t-test revealed a significant upregulation of xCT expression in NAc in Augmentin-treated group as compared to control group (Fig. 3C,D) , (t(12) = 3.588, p < 0.01). In addition, statistical analysis using independent t-test revealed a significant upregulation of xCT expression in the PFC in Augmentin-treated group as compared to control group (Fig. 4C,D) , (t(12) = 2.221, p < 0.05). However, statistical analysis using independent t-test did not reveal any significant difference in GLAST expression in the NAc (Fig. 3E,F ; t(12) = 0.7122) and the PFC (Fig. 4E,F ; t(12) = 1.786) between Augmentin-treated group and control group.
Discussion
We report in this study that oral gavage of Augmentin (100 mg/kg) significantly reduced daily ethanol intake in male P rats. In addition, oral gavage of Augmentin resulted in a significant decrease in ethanol preference. However, oral gavage of Augmentin exhibited a significant increase in the water intake starting from Day 2 throughout Day 5. Oral gavage of Augmentin did not cause any change in the body weight of the treated rats as compared to the control group. Importantly, oral gavage of Augmentin upregulated the expression of GLT-1 and xCT in the NAc and the PFC. Conversely, oral gavage of Augmentin did not change the expression of GLAST in the NAc or the PFC. Central brain reward regions, particularly NAc and PFC contain a relatively high concentration of glutamate, which plays an important role in the development of dependence related changes in cognition, sensory input, emotion and subsequent motor output [30] . Drug reinforcement has been suggested to involve the glutamatergic projections from the PFC, particularly to the NAc, during craving in commonly abused drugs such as nicotine, ethanol, heroin and cocaine [1, [31] [32] [33] [34] [35] [36] . Dysregulation of these projections from the PFC may play critical role in the development of drug dependence such as cocaine and heroin [35, 36] . Moreover, PFC receives glutamatergic projections from other brain regions, including amygdala and hippocampus [37, 38] . Studies from our laboratory found that chronic ethanol exposure downregulated xCT expression in the PFC. Importantly, ␤-lactams including, ceftriaxone and Augmentin, upregulated xCT expression in PFC and this effect was associated, at least in part, with reduction of ethanol intake [16, 25] . We suggest here that downregulation of xCT expression may lead to alteration in glutamate homeostasis in the PFC, and Augmentin may overcome this effect through upregulation of this xCT protein as well as GLT-1. It is well known that downregulation of GLT-1 and xCT expression was found associated with an increase in extracellular glutamate concentration in NAc in animal model of cocaine seeking [17, 39] .
Several studies have demonstrated that ethanol exposure is associated with increased extracellular glutamate concentration in the NAc [5, 40, 41] . In addition, downregulation of GLT-1 expression has been reported following exposure to chronic ethanol [8, 9, 16] and other drugs of abuse [39, 42] . In fact, it was shown that downregulation of GLT-1 following chronic ethanol exposure was associated with an elevation in extracellular glutamate concentration in NAc [5] . Interestingly, several reports have demonstrated the upregulatory effect of ␤-lactams parenteral administration on GLT-1 and xCT expression in the central reward brain regions [5, 24, 25, 39, 43] .
Importantly, identifying an orally active compound that can be used to alleviate drug dependence is clinically relevant. Oral gavage delivery route would decrease the risk of injection site infection or tissue necrosis and this may prevent potential complications. Oral route of medications is considered a better alternative option to overcome the pain and discomfort associated with parenteral administrations. In addition, oral route of medications is cost-effective in comparison to parenteral medications, where parenteral route requires sterile and isotonic formula. Moreover, oral delivery route would increase the patient's compliance over the parenteral route of administration [44, 45] . Thus, to the best of our knowledge, this present study is the first to investigate the effect of oral gavage of ␤-lactam, such as Augmentin on ethanol drinking and the expression of glutamate transporters.
It is important to note that ceftriaxone 2-day treatment attenuated ethanol consumption from Day 1 [22] . However, GLT-1 and xCT expression were upregulated in the PFC but not the NAc. Moreover, ceftriaxone 5-day treatment revealed reduction of ethanol consumption and upregulation of GLT-1 and xCT expression in the NAc and the PFC [22] . In this study, oral gavage of Augmentin at a dose of 100 mg/kg for five consecutive days decreased the ethanol consumption from Day 2 through Day 5 compared to the control. The reduction of ethanol intake found as early as Day 2 might be due to either an increase in the activity of xCT and GLT-1 or other unknown pharmacological effects that are warranted further investigation. This attenuation in ethanol consumption was associated with significant elevation of water intake. Similarly, several studies have reported that reduction in ethanol consumption was associated with an increase of water intake [24, 27, 46] . We suggest this increase in water intake is a compensatory mechanism for the reduction in ethanol consumption in order to maintain the fluid intake in P rat model. This compensatory mechanism might also be compared to the increase in water intake that was observed in a previous study conducted on the high ethanol consuming rat model [47] . Moreover, oral gavage of Augmentin decreased the ethanol preference.
In this study, we examined the effect of oral gavage of Augmentin on the upregulation of GLT-1 and xCT, which might restore glutamate homeostasis. We found that in association with the reduction of ethanol consumption, oral gavage of Augmentin revealed a significant upregulation of GLT-1 expression in the NAc and PFC. Moreover, several studies have reported that administration of ␤-lactams upregulated GLT-1 expression in mesocorticolimbic brain regions [16, 25, 43, 48] . This effect was, at least in part, associated with a reduction of ethanol consumption [16, 48] and normalization of extracellular glutamate concentration in NAc [5] .
xCT plays a crucial role in regulating the extracellular glutamate homeostasis. xCT can regulate the release of glutamate indirectly [49, 50] . It is noteworthy that decreased xCT expression in the NAc can lead to reduction in the glutamatergic tone on metabotropic receptor 2/3 (mGluR2/3) [51, 52] . Lower glutamatergic tone on mGluR2/3 can lead to a higher release of glutamate, which plays a key role in drug dependence and reinstatement [14, 35, 51] . Importantly, studies have reported significant changes in xCT activity and expression in different drug dependence and drug-relapse animal studies [17, 42, 53, 54] . Moreover, xCT is proposed to play an important role in ␤-lactam's neuroprotective activity [55] . In addition, several studies have reported that ␤-lactam antibiotics induced a reduction in ethanol consumption, at least in part, by the upregulatory effect of xCT expression in the NAc and the PFC [16, 22, 24, 25] . Similarly, this study showed that oral gavage of Augmentin induced an upregulation of xCT expression in the NAc and the PFC. The possibility of involvement of other mechanisms in the reduction of ethanol consumption, such as disruption of taste or smell, is a novel area of research that remains unexplored. Further investigations are warranted to examine the effect of ␤-lactams on taste or smell and its possible interactions with ethanol consumption.
Oral gavage of Augmentin did not change the expression of GLAST in the NAc and the PFC. This finding might be explained by the fact that GLAST is predominant glutamate transporter in the cerebellum as compared to the forebrain regions [18] . Moreover, studies have demonstrated the important role of GLAST in other peripheral organs such as the retina [56] and the inner ear [57] . Furthermore, previous studies demonstrated also that other ␤-lactam antibiotics treatment did not reveal any difference in GLAST expression as compared to the control group [24, 58, 59] .
Augmentin contains amoxicillin and clavulanic acid in a 4:1 (amoxicillin: clavulanate) ratio. Both compounds have a central ␤-lactam core which is proposed to be the reason for the upregulatory effect on GLT-1 [21] . Importantly, clavulanic acid also has been reported to upregulate GLT-1 expression, which was associated with reduction in reinforcing effects of cocaine in mice [43] . Studies are warranted to investigate the role of clavulanic acid in ethanol dependence. Our findings provide the first evidence that orally administered ␤-lactam compounds can reduce ethanol consumption presumably by restoring glutamate homeostasis due to the upregulatory effects on GLT-1 and xCT expression in mesocorticolimbic brain regions.
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